Press Release
<< Back
Verastem to Present New Data at the 12th International Mesothelioma Interest Group Conference
Investigators and members of the
Professor
“We are honored to have been selected for several presentations at this
year’s iMig Conference and to participate with other industry and
medical leaders in the fight against mesothelioma,” said Dr.
The schedule for the presentations is as follows:
iMig Special Keynote Lecture: “Cancer Stem Cells as
Presenter:
Presentation Title: “Determination of Biomarker response in a
Phase II Window of Opportunity Study of Defactinib (VS-6063), a
Focal Adhesion Kinase (FAK) Inhibitor, in Subjects with Resectable MPM”
Presenter:
Presentation Title: “FAK Inhibitor VS-6063 (Defactinib) Targets
Mesothelioma Cancer Stem Cells which are Enriched by Standard of Care
Chemotherapy”
Presenter:
Presentation Title: “The Cancer Stem Cell Inhibitors VS-6063
(Defactinib) and VS-5584 Exhibit Synergistic Anticancer Activity in
Preclinical Models of Mesothelioma”
Presenter:
About Malignant Pleural Mesothelioma
Malignant pleural mesothelioma is an aggressive form of cancer that
occurs in the mesothelium, the thin layer of tissue that covers the
lungs. Mesothelioma is associated with exposure to asbestos in most
cases. According to the
About VS-6063
VS-6063 (Defactinib) is an orally available compound designed to target
cancer stem cells through the potent inhibition of focal adhesion kinase
(FAK). Cancer stem cells are an underlying cause of tumor resistance to
chemotherapy, recurrence and ultimate disease progression. Research by
About VS-5584
VS-5584 is an orally available compound that has demonstrated potent and
highly selective activity against class 1 PI3K enzymes and dual
inhibitory actions against mTORC1 and mTORC2. In preclinical studies,
VS-5584 has been shown to reduce the percentage of cancer stem cells and
induce tumor regression in chemotherapy-resistant models.
About
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development of the Company’s compounds, including VS-6063,
or defactinib and VS-5584 and the Company’s FAK inhibition and PI3K/mTOR
programs generally, the timeline for clinical development and regulatory
approval of the Company’s compounds, the expected timing for the
reporting of data from ongoing trials, and the structure of the
Company’s planned or pending clinical trials. The words “anticipate,”
“appear,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,”
“predict,” “project,” “target,” “potential,” “will,” “would,” “could,”
“should,” “continue,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Each forward-looking statement is
subject to risks and uncertainties that could cause actual results to
differ materially from those expressed or implied in such statement.
Applicable risks and uncertainties include the risks that the
preclinical testing of the Company’s compounds and preliminary data from
clinical trials may not be predictive of the results or success of
ongoing or later clinical trials, that data may not be available when we
expect it to be, that enrollment of clinical trials may take longer than
expected, that the Company will be unable to successfully complete the
clinical development of its compounds, including VS-6063 and VS-5584,
that the development of the Company’s compounds will take longer or cost
more than planned, and that the Company’s compounds will not receive
regulatory approval or become commercially successful products. Other
risks and uncertainties include those identified under the heading “Risk
Factors” in the Company’s Annual Report on Form 10-K for the year ended
Source:
Verastem, Inc.
Brian Sullivan, 617-252-9314
bsullivan@verastem.com